1	Genetics	_	NNP	_	_	2	NAME	_	_
2	Institute	_	NNP	_	_	9	SBJ	_	_
3	Inc.	_	NNP	_	_	2	POSTHON	_	_
4	,	_	,	_	_	2	P	_	_
5	Cambridge	_	NNP	_	_	7	NAME	_	_
6	,	_	,	_	_	7	P	_	_
7	Mass.	_	NNP	_	_	2	LOC	_	_
8	,	_	,	_	_	2	P	_	_
9	said	_	VBD	_	_	0	ROOT	_	_
10	it	_	PRP	_	_	11	SBJ	_	_
11	was	_	VBD	_	_	9	OBJ	_	_
12	awarded	_	VBN	_	_	11	VC	_	_
13	U.S.	_	NNP	_	_	14	NMOD	_	_
14	patents	_	NNS	_	_	12	OBJ	_	_
15	for	_	IN	_	_	12	ADV	_	_
16	Interleukin-3	_	NN	_	_	15	PMOD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	bone	_	NN	_	_	20	NMOD	_	_
19	morphogenetic	_	JJ	_	_	20	NMOD	_	_
20	protein	_	NN	_	_	17	CONJ	_	_
21	.	_	.	_	_	9	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	patent	_	NN	_	_	5	SBJ	_	_
3	for	_	IN	_	_	2	NMOD	_	_
4	Interleukin-3	_	NN	_	_	3	PMOD	_	_
5	covers	_	VBZ	_	_	0	ROOT	_	_
6	materials	_	NNS	_	_	5	OBJ	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	methods	_	NNS	_	_	7	CONJ	_	_
9	used	_	VBN	_	_	6	APPO	_	_
10	to	_	TO	_	_	9	OPRD	_	_
11	make	_	VB	_	_	10	IM	_	_
12	the	_	DT	_	_	17	NMOD	_	_
13	human	_	JJ	_	_	17	NMOD	_	_
14	blood	_	NN	_	_	17	NMOD	_	_
15	cell	_	NN	_	_	17	NMOD	_	_
16	growth	_	NN	_	_	17	NMOD	_	_
17	factor	_	NN	_	_	11	OBJ	_	_
18	via	_	IN	_	_	11	MNR	_	_
19	recombinant	_	JJ	_	_	21	NMOD	_	_
20	DNA	_	NNP	_	_	21	NMOD	_	_
21	technology	_	NN	_	_	18	PMOD	_	_
22	.	_	.	_	_	5	P	_	_

1	Sandoz	_	NNP	_	_	3	SBJ	_	_
2	Ltd.	_	NNP	_	_	1	POSTHON	_	_
3	has	_	VBZ	_	_	0	ROOT	_	_
4	licensed	_	VBN	_	_	3	VC	_	_
5	certain	_	JJ	_	_	6	NMOD	_	_
6	manufacturing	_	NN	_	_	4	OBJ	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	marketing	_	NN	_	_	9	NMOD	_	_
9	rights	_	NNS	_	_	7	CONJ	_	_
10	for	_	IN	_	_	6	NMOD	_	_
11	Interleukin-3	_	NN	_	_	10	PMOD	_	_
12	from	_	IN	_	_	4	ADV	_	_
13	Genetics	_	NNP	_	_	14	NAME	_	_
14	Institute	_	NNP	_	_	12	PMOD	_	_
15	and	_	CC	_	_	3	COORD	_	_
16	is	_	VBZ	_	_	15	CONJ	_	_
17	conducting	_	VBG	_	_	16	VC	_	_
18	preclinical	_	JJ	_	_	19	NMOD	_	_
19	studies	_	NNS	_	_	17	OBJ	_	_
20	with	_	IN	_	_	17	MNR	_	_
21	it	_	PRP	_	_	20	PMOD	_	_
22	.	_	.	_	_	3	P	_	_

1	Interleukin-3	_	NN	_	_	2	SBJ	_	_
2	may	_	MD	_	_	24	OBJ	_	_
3	help	_	VB	_	_	2	VC	_	_
4	in	_	IN	_	_	3	ADV	_	_
5	treating	_	VBG	_	_	4	PMOD	_	_
6	blood	_	NN	_	_	8	NMOD	_	_
7	cell	_	NN	_	_	8	NMOD	_	_
8	deficiencies	_	NNS	_	_	5	OBJ	_	_
9	associated	_	VBN	_	_	8	APPO	_	_
10	with	_	IN	_	_	9	ADV	_	_
11	cancer	_	NN	_	_	12	NMOD	_	_
12	treatment	_	NN	_	_	10	PMOD	_	_
13	,	_	,	_	_	12	P	_	_
14	bone	_	NN	_	_	16	NMOD	_	_
15	marrow	_	NN	_	_	16	NMOD	_	_
16	transplants	_	NNS	_	_	12	COORD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	other	_	JJ	_	_	20	NMOD	_	_
19	blood-cell	_	NN	_	_	20	NMOD	_	_
20	disorders	_	NNS	_	_	17	CONJ	_	_
21	,	_	,	_	_	24	P	_	_
22	Genetics	_	NNP	_	_	23	NAME	_	_
23	Institute	_	NNP	_	_	24	SBJ	_	_
24	said	_	VBD	_	_	0	ROOT	_	_
25	.	_	.	_	_	24	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	second	_	JJ	_	_	3	NMOD	_	_
3	patent	_	NN	_	_	4	SBJ	_	_
4	describes	_	VBZ	_	_	0	ROOT	_	_
5	bone	_	NN	_	_	7	NMOD	_	_
6	morphogenetic	_	JJ	_	_	7	NMOD	_	_
7	protein-1	_	NN	_	_	4	OBJ	_	_
8	,	_	,	_	_	7	P	_	_
9	a	_	DT	_	_	10	NMOD	_	_
10	substance	_	NN	_	_	7	APPO	_	_
11	that	_	WDT	_	_	12	SBJ	_	_
12	can	_	MD	_	_	10	NMOD	_	_
13	induce	_	VB	_	_	12	VC	_	_
14	formation	_	NN	_	_	13	OBJ	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	new	_	JJ	_	_	17	NMOD	_	_
17	cartilage	_	NN	_	_	15	PMOD	_	_
18	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	patent	_	NN	_	_	3	SBJ	_	_
3	covers	_	VBZ	_	_	21	OBJ	_	_
4	BMP-1	_	NN	_	_	6	NMOD	_	_
5	type	_	NN	_	_	6	NMOD	_	_
6	proteins	_	NNS	_	_	3	OBJ	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	pharmaceutical	_	JJ	_	_	9	NMOD	_	_
9	compositions	_	NNS	_	_	7	CONJ	_	_
10	and	_	CC	_	_	9	COORD	_	_
11	methods	_	NNS	_	_	10	CONJ	_	_
12	for	_	IN	_	_	9	NMOD	_	_
13	treating	_	VBG	_	_	12	PMOD	_	_
14	bone	_	NN	_	_	13	OBJ	_	_
15	or	_	CC	_	_	14	COORD	_	_
16	cartilage	_	NN	_	_	17	NMOD	_	_
17	defects	_	NNS	_	_	15	CONJ	_	_
18	,	_	,	_	_	21	P	_	_
19	Genetics	_	NNP	_	_	20	NAME	_	_
20	Institute	_	NNP	_	_	21	SBJ	_	_
21	said	_	VBD	_	_	0	ROOT	_	_
22	.	_	.	_	_	21	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	3	SBJ	_	_
3	added	_	VBD	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	OBJ	_	_
5	it	_	PRP	_	_	6	SBJ	_	_
6	has	_	VBZ	_	_	4	SUB	_	_
7	filed	_	VBN	_	_	6	VC	_	_
8	patent	_	NN	_	_	9	NMOD	_	_
9	applications	_	NNS	_	_	7	OBJ	_	_
10	``	_	``	_	_	7	P	_	_
11	on	_	IN	_	_	7	ADV	_	_
12	a	_	DT	_	_	14	NMOD	_	_
13	large	_	JJ	_	_	14	NMOD	_	_
14	number	_	NN	_	_	11	PMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	different	_	JJ	_	_	18	NMOD	_	_
17	BMP	_	NN	_	_	18	NMOD	_	_
18	proteins	_	NNS	_	_	15	PMOD	_	_
19	''	_	''	_	_	7	P	_	_
20	and	_	CC	_	_	3	COORD	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	patent	_	NN	_	_	25	SBJ	_	_
23	on	_	IN	_	_	22	NMOD	_	_
24	BMP-1	_	NN	_	_	23	PMOD	_	_
25	is	_	VBZ	_	_	20	CONJ	_	_
26	the	_	DT	_	_	27	NMOD	_	_
27	first	_	JJ	_	_	25	PRD	_	_
28	it	_	PRP	_	_	29	SBJ	_	_
29	has	_	VBZ	_	_	27	NMOD	_	_
30	received	_	VBN	_	_	29	VC	_	_
31	.	_	.	_	_	3	P	_	_

1	BMP	_	NN	_	_	2	NMOD	_	_
2	products	_	NNS	_	_	3	SBJ	_	_
3	may	_	MD	_	_	24	OBJ	_	_
4	be	_	VB	_	_	3	VC	_	_
5	useful	_	JJ	_	_	4	PRD	_	_
6	in	_	IN	_	_	4	ADV	_	_
7	fracture	_	NN	_	_	8	NMOD	_	_
8	healing	_	NN	_	_	6	PMOD	_	_
9	and	_	CC	_	_	6	COORD	_	_
10	in	_	IN	_	_	9	CONJ	_	_
11	treating	_	VBG	_	_	10	PMOD	_	_
12	bone	_	NN	_	_	13	NMOD	_	_
13	loss	_	NN	_	_	11	OBJ	_	_
14	associated	_	VBN	_	_	13	APPO	_	_
15	with	_	IN	_	_	14	ADV	_	_
16	periodontal	_	JJ	_	_	17	NMOD	_	_
17	disease	_	NN	_	_	15	PMOD	_	_
18	and	_	CC	_	_	17	COORD	_	_
19	certain	_	JJ	_	_	20	NMOD	_	_
20	cancers	_	NNS	_	_	18	CONJ	_	_
21	,	_	,	_	_	24	P	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	company	_	NN	_	_	24	SBJ	_	_
24	said	_	VBD	_	_	0	ROOT	_	_
25	.	_	.	_	_	24	P	_	_

